Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
Elisabetta Vergani, Lorenza Di Guardo, Matteo Dugo, Sara Rigoletto, Gabrina Tragni, Roberta Ruggeri, Federica Perrone, Elena Tamborini, Annunziata Gloghini, Flavio Arienti, Barbara Vergani, Paola Deho, Loris De Cecco, Viviana Vallacchi, Paola Frati, Eriomina Shahaj
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMelanoma and MAPK Pathways · Cutaneous Melanoma Detection and Management · Nanoplatforms for cancer theranostics
This article has been corrected: Following an investigation into concerns raised by a third party, we have identified image panel duplication involving the loading control (Vinculin) of the COX-2 Western blot in Figure 5E and the vinculin blot in Figure 2C. The authors have agreed with the identified issue and provided the uncropped, unmodified blots from their original experiment. They have also prepared a corrected version of Figure 5E, which is included below. The authors have stated that these corrections do not alter the original results or conclusions of the paper.
Original article: Oncotarget. 2016; 7:4428–4441. 4428-4441. https://doi.org/10.18632/oncotarget.6599